Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
GSK 329 is a potent and selective TNNI3K (cardiac troponin I-interacting kinase) inhibitor (IC50 = 10 nM). It exhibits selectivity for TNNI3K over human VEGFR2 (40-fold), p38α (80-fold), B-Raf (>200-fold) and displays >100-fold selectivity over 80% of 185 kinases tested. In vivo, GSK 329 reduces infarct size, ROS levels, and p38 activation in a mouse model of ischemia/reperfusion cardiac injury. This compound is orally bioavailable.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
The following data is based on the product molecular weight 472.25. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.12 mL||10.59 mL||21.18 mL|
|5 mM||0.42 mL||2.12 mL||4.24 mL|
|10 mM||0.21 mL||1.06 mL||2.12 mL|
|50 mM||0.04 mL||0.21 mL||0.42 mL|
References are publications that support the biological activity of the product.
Patterson et al (2021) Identification of diarylurea inhibitors of the cardiac-specific kinase TNNI3K by designing selectivity against VEGFR2, p38a, and B-Raf. J.Med.Chem. 64 15651 PMID: 34699203
Vagnozzi et al (2013) Inhibition of the cardiomyocyte-specific kinase TNNI3K limits oxidative stress, injury, and adverse remodeling in the ischemic heart. Sci.Transl.Med. 5 207ra141 PMID: 24132636
If you know of a relevant reference for GSK 329, please let us know.
Keywords: GSK 329, GSK 329 supplier, GSK329, potent, selective, TNNI3K, inhibitors, inhibiTS, orally, bioavailable, kinases, MAPK, ischemia/reperfusion, cardiac, injury, in, vivo, Other, 7637, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for GSK 329. Do you know of a great paper that uses GSK 329 from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review GSK 329 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
MAP kinase signaling is integral to the regulation of numerous cellular processes such as proliferation and differentiation, and as a result is an important focus of cancer and immunology research. Updated for 2016, this review discusses the regulation of the MAPK pathway and properties of MAPK cascades. Compounds available from Tocris are listed.